Valuation: NEOVACS

Market Cap 4.09K 4.73K 3.84K 3.49K 6.57K 453K 6.68K 45.02K 17.6K 227K 17.77K 17.39K 753K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -233K -189K -172K -323K -22.25M -328K -2.21M -865K -11.14M -874K -855K -37.03M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
1 day-8.80%
1 week-44.83%
Current month-6.29%
1 month-31.59%
3 months-65.80%
6 months-95.72%
Current year-99.21%
1 week 0.68
Extreme 0.6841
1.43
1 month 0.68
Extreme 0.68
1.43
Current year 0.68
Extreme 0.68
267
1 year 0.68
Extreme 0.68
8,899
3 years 0.68
Extreme 0.68
32,000,000
5 years 0.68
Extreme 0.68
351,920,000
10 years 0.68
Extreme 0.68
351,920,000
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2020-09-30
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 2003-05-27
Director/Board Member - 2020-04-30
Chairman - -
Date Insider Type Main position Quantity % Market Cap.
2/27/21 Sell

Chief Executive Officer

2,505,144 1.3796%
2/23/21 Sell

Chief Executive Officer

6,391,053 3.5196%
2/23/21 Sell

Chief Executive Officer

1,108,947 0.6107%
Change 5-day change 1-year change 3-year change Capi.($)
-8.80%-44.83%-99.99%-100.00% 126K
-1.78%-1.68%+1.48%+15.31% 48.42B
+0.85%-0.70%+460.88%+563.55% 43.66B
-2.40%-0.23%+8.13%+71.41% 39.51B
-2.01%-0.85%+23.85%+8.73% 38.95B
-0.50%+0.85%+20.60%+49.65% 32.61B
+0.38%-3.23% - - 16.32B
-0.59%-2.06%+26.35%+118.09% 16.15B
+0.49%+0.92%+4.11%+23.67% 14.16B
-0.43%+4.70%+78.74%+33.31% 13.37B
Average -1.48%-4.04%+58.24%+87.08% 26.31B
Weighted average by Cap. -0.91%+0.59%+95.83%+132.95%

Financials

2023 2024
Net sales 533K 618K 501K 456K 857K 59.06M 871K 5.87M 2.3M 29.57M 2.32M 2.27M 98.28M 434K 502K 408K 371K 697K 48.04M 709K 4.78M 1.87M 24.06M 1.89M 1.85M 79.95M
Net income -8.74M -10.12M -8.22M -7.47M -14.05M -968M -14.28M -96.27M -37.64M -485M -38.01M -37.18M -1.61B -32.91M -38.11M -30.93M -28.13M -52.88M -3.64B -53.76M -362M -142M -1.82B -143M -140M -6.06B
Net Debt -237K -274K -222K -202K -380K -26.18M -386K -2.6M -1.02M -13.11M -1.03M -1.01M -43.57M -205K -237K -193K -175K -330K -22.71M -335K -2.26M -883K -11.37M -891K -872K -37.78M
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
16
Date Price Change Volume
26-08-14 €0.6841 -8.80% 67,476
26-08-13 €0.7501 -6.24% 57,062
26-08-12 €0.8000 -20.76% 85,188
26-08-11 €1.010 -14.44% 26,133
26-08-10 €1.180 -4.84% 55,132
  1. Stock Market
  2. Stocks
  3. ALNEV Stock